Table 1: Overview of key information.
|
|
Patient 1 |
Patient 2 |
Patient 3 |
Patient 4 |
|
Age at diagnosis |
51 |
30 |
52 |
26 |
|
Sex |
Male |
Male |
Male |
Male |
|
Presenting symptoms |
Headaches; blurry vision; photophobia; diminished libido/spontaneous erections |
Visual field deficits; blurry vision; headaches; diminished libido |
Headaches; diminished libido/spontaneous erections |
Headaches; vision loss; fatigue; diminished libido |
|
Tumor size at diagnosis (AP × CC × TV) [cm] |
3.7 × 5.4 × 2.9 |
2.5 × 3.5✢ |
4.5 × 5.2 × 4.8 |
2.0 × 3.4 × 2.2 |
|
Tumor size pre-operatively (AP × CC × TV) [cm] |
3.7 × 4.1 × 2.7 |
2.6 × 3.3 × 3.0 |
4.4 × 5.6 × 5.5 |
- |
|
Duration of cabergoline treatment (months) |
1 |
6 |
2 |
0 |
|
Amount of tumor fibrosis (%) |
60-70 |
50-60 |
50-60 |
15 |
|
Patient outcomes |
Symptom improvement; PRL normalization; GTR |
Symptom improvement; STR |
Symptom improvement; initial PRL normalization, followed by PRL elevation |
Symptom improvement; no PRL normalization; GTR |
|
Post-operative cabergoline advised? |
No |
No |
Yes* |
Yes |
|
Lost to follow-up? |
Yes |
Yes |
Yes |
Yes |
AP: Anterior-Posterior; CC: Cranio-Caudal; TV: Transverse; PRL: Prolactin; ✢: Full dimensions were unavailable as scans were completed at an outside institution; *: Patient was lost to follow-up before cabergoline was provided